Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Purification and characterization of 2 functionally distinct forms of C-1 inhibitor from a patient with angioedema

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Curd, J. G.
  • Yelvington, M.
  • Ziccardi, R. J.
  • Mathison, D. A.
  • Griffin, John

publication date

  • 1981

journal

  • Clinical and Experimental Immunology  Journal

abstract

  • A minority of patients with hereditary angioedema (HAE) have normal concentrations of a dysfunctional C1 inhibitor protein (C1INH) in their plasmas. We purified C1INH from the plasmas of one such patient before and during treatment with the anabolic steroid stanozolol. Both the pretreatment plasma and plasma obtained during stanozolol treatment contained varying amounts of two extremely similar C1INH proteins that were functionally distinct. The pretreatment plasma contained primarily (94%) dysfunctional C1INH that did not inactivate or complex with either purified C1s, activated Hageman factor, or kallikrein and small amounts (6%) of functionally normal C1INH. Stanozolol treatment increased the plasma concentrations of both of these proteins as well as the proportion (23%) of functional C1INH in the plasma. The purified dysfunctional and functional C1INHs had identical or nearly identical molecular sizes, charges, amino acid compositions, and amino sugar contents, and could not be distinguished physicochemically from each other or from normal C1INH. From these studies of purified C1INH proteins we concluded that HAE associated with dysfunctional C1INH is due to a defect at the structural locus for one C1INH gene and that both the dysfunctional C1INH gene and the normal C1INH gene products are present in the plasma of the affected subject. Treatment with stanozolol comparably increased the synthesis of both C1INH proteins. The disproportionate rise in the level of the normal C1INH protein is consistent with the view that it is more rapidly catabolized as a consequence of its interaction with the proteases it inactivates.

subject areas

  • Adult
  • Amino Acids
  • Angioedema
  • Complement Activating Enzymes
  • Complement C1 Inactivator Proteins
  • Complement C1s
  • Factor XII
  • Female
  • Humans
  • Kallikreins
  • Stanozolol
scroll to property group menus

Identity

PubMed Central ID

  • PMC1537389

International Standard Serial Number (ISSN)

  • 0009-9104

PubMed ID

  • 6976242
scroll to property group menus

Additional Document Info

start page

  • 261

end page

  • 270

volume

  • 45

issue

  • 2

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support